122 related articles for article (PubMed ID: 7519674)
1. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
Montaner JS; Rachlis A; Beaulieu R; Gill J; Schlech W; Phillips P; Auclair C; Boulerice F; Schindzielorz A; Smaldone L
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):924-30. PubMed ID: 7519674
[TBL] [Abstract][Full Text] [Related]
2. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
Rathbun RC; Martin ES
Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
[TBL] [Abstract][Full Text] [Related]
3. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
d'Arminio Monforte A; Musicco M; Galli M; Paga C; La Regina A; Lazzarin A; Angarano G; Milazzo F; Gritti F; Arlotti M; Mazzotta F; Visco G; Aiuti F; Moroni M
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):135-42. PubMed ID: 9105840
[TBL] [Abstract][Full Text] [Related]
4. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
6. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
Gatell JM; Leal M; Mallolas J; Vidal C; Pumarola T; Parra R; Padró S; Caruz A; Falgueras T; Rey C; Sánchez-Quijano A; Torres Y; Lissen E; Jiménez de Anta MT; Soriano E
Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM
Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Mauss S; Adams O; Willers R; Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592
[TBL] [Abstract][Full Text] [Related]
9. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
[TBL] [Abstract][Full Text] [Related]
11. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
[TBL] [Abstract][Full Text] [Related]
13. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
AIDS; 1996 Jul; 10(8):867-80. PubMed ID: 8828744
[TBL] [Abstract][Full Text] [Related]
14. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Delta Coordinating Committee
HIV Med; 2001 Jul; 2(3):181-8. PubMed ID: 11737399
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine.
Allan JD; Connolly KJ; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S46-51. PubMed ID: 8425019
[TBL] [Abstract][Full Text] [Related]
16. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
[TBL] [Abstract][Full Text] [Related]
17. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
18. Didanosine.
Shelton MJ; O'Donnell AM; Morse GD
Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
